Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Royalty Pharma
Biotech
Zealand sells rights to Takeda’s blood cancer drug for $100M
As the FDA mulls whether to approve Takeda and Protagonist’s rusfertide, Zealand sold its rights to the blood cancer drug in return for $100 million.
James Waldron
Aug 13, 2026 5:05am
Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales
Jul 22, 2026 10:01am
J&J, Royalty to co-fund $500M autoimmune antibody program
Mar 30, 2026 10:07am
Teva lines up $500M in Royalty Pharma funding for vitiligo drug
Jan 12, 2026 7:10am
Royalty's $275M financing deal for Denali drug awaiting FDA nod
Dec 4, 2025 10:20am
Royalty bestows Zenas with $300M for autoimmune approval push
Sep 2, 2025 11:07am
